Graft-versus-host disease prevention by rapamycin: cellular mechanisms.

Understanding the cellular mechanisms that lead to graft-versus-host disease (GVHD) may lead to alternative approaches in the prevention or therapy of this disease process. In this manuscript, we investigated the mechanisms of action of the immunosuppressive drug rapamycin for the prevention of GVHD. GVHD-free long-term survival was achieved in BALB/c (H2d, Mls-2a, Mls-3a) recipients of B10.D2/nSnJ (H-2d, Mls-2a, Mls-3a) bone marrow and spleen cells after a 30-day course of high-dose rapamycin (5 mg/kg per day). Low responses to recipient and third-party cells in a mixed lymphocyte reaction (MLR) were observed as well as decreased mature T-cell numbers in the spleen. This low response was not due to defective interleukin (IL)-2 production, because exogenous IL-2 did not improve the responses in the MLR. However, GVHD-free long-term survival was associated with a large number of infiltrating mononuclear cells in the target organs of GVHD. This observation suggested the possibility that these cells were responsible for suppressing the immune response. Regulatory cells, which could suppress both antirecipient and third-party responses in vitro, were demonstrated to be present in the spleens of these GVHD-free long-term survivors. These results suggest that in addition to impaired cellular immune function, the presence of non-specific regulatory cells (ie, suppression) may contribute to maintenance of GVHD-free long-term survival induced by short-course rapamycin.

• Publication year

  2000

• Venue

  Biology of Blood and Marrow Transplantation

• Publication date

  2000-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S1083-8791(00)70062-0PMID 11071258
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A CD4+T-cell subset inhibits antigen-specific T-cell responses and prevents colitis

  1997cited by this paper
• Pros and cons of stem cell transplantation for autoimmune disease.

  1997cited by this paper
• The effects of chimeric cells following donor bone marrow infusions as detected by PCR-flow assays in kidney transplant recipients.

  1997cited by this paper
• Outcome of autologous rescue after failed engraftment of allogeneic marrow.

  1996cited by this paper
• Inhibition of T cell costimulation by VCAM-1 prevents murine graft-versus-host disease across minor histocompatibility barriers.

  1995cited by this paper
• Reversal of Graft-Versus-Host Disease with Infusion of Autologous Bone Marrow

  1994cited by this paper
• Rapamycin-induced long-term allograft survival depends on persistence of alloantigen.

  1994cited by this paper
• Which way for drug-mediated immunosuppression?

  1994cited by this paper
• Blockade of the CD28 co-stimulatory pathway: a means to induce tolerance.

  1994cited by this paper
• Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prophylaxis of acute graft-versus-host disease.

  1993cited by this paper
• Murine recipients of fully mismatched donor marrow are protected from lethal graft-versus-host disease by the in vivo administration of rapamycin but develop an autoimmune-like syndrome.

  1993cited by this paper
• Rapamycin suppression of host-versus-graft and graft-versus-host disease in MHC-mismatched rats.

  1992cited by this paper
• Graft versus host disease following allogeneic bone marrow transplantation.

  1992cited by this paper
• Studies of CD4- CD8- alpha beta bone marrow T cells with suppressor activity.

  1992cited by this paper
• Altered antigen receptor signaling in anergic T cells from self-tolerant T-cell receptor beta-chain transgenic mice.

  1991cited by this paper
• The effect of the immunosuppressant FK‐506 on alternate pathways of T cell activation

  1991cited by this paper
• In vitro and in vivo analysis of bone marrow-derived CD3+, CD4-, CD8-, NK1.1+ cell lines.

  1990cited by this paper
• Extrathymic tolerance of mature T cells: clonal elimination as a consequence of immunity.

  1990cited by this paper
• CYCLOSPORINE, FK506, AND RAPAMYCIN: SOME EFFECTS ON EARLY ACTIVATION EVENTS IN SERUM‐FREE, MITOGEN‐STIMULATED MOUSE SPLEEN CELLS

  1990cited by this paper
• Distinct mechanisms of suppression of murine T cell activation by the related macrolides FK-506 and rapamycin.

  1990cited by this paper
• In vivo induction of anergy in peripheral V beta 8+ T cells by staphylococcal enterotoxin B

  1990cited by this paper
• Cloned natural suppressor cell lines express the CD3+CD4-CD8- surface phenotype and the alpha, beta heterodimer of the T cell antigen receptor.

  1989cited by this paper
• Tolerance of class I histocompatibility antigens expressed extrathymically

  1989cited by this paper
• Clonal anergy induced in mature Vβ6+ T lymphocytes on immunizing Mls-1b mice with Mls-1a expressing cells

  1989cited by this paper
• A nondeletional mechanism of thymic self tolerance.

  1989cited by this paper
• A Guide to Bone Marrow Transplantation

  1988cited by this paper
• Tolerance in T-cell-receptor transgenic mice involves deletion of nonmature CD4+8+ thymocytes

  1988cited by this paper
• Mechanism of protection from graft-vs-host disease in murine mixed allogeneic chimeras. I. Development of a null cell population suppressive of cell-mediated lympholysis responses and derived from the syngeneic bone marrow component.

  1988cited by this paper
• Role of lymphokine-activated killer cells as mediators of veto and natural suppression.

  1988cited by this paper
• Genetic and stimulator cell requirements for generation and activation of minor histocompatibility antigen-specific memory cytotoxic T-lymphocyte precursors.

  1988cited by this paper
• Variable capacity of L3T4+ T cells to cause lethal graft-versus-host disease across minor histocompatibility barriers in mice

  1987cited by this paper
• Cloned natural suppressor cells prevent lethal graft-vs-host disease.

  1987cited by this paper
• Tumor necrosis factor/cachectin is an effector of skin and gut lesions of the acute phase of graft-vs.-host disease

  1987cited by this paper
• L3T4-positive T cells participate in the induction of graft-vs-host disease in response to minor histocompatibility antigens.

  1987cited by this paper
• A T cell receptor Vβ segment that imparts reactivity to a class II major histocompatibility complex product

  1987cited by this paper
• Advantages of detecting monoclonal antibody binding to tissue sections with biotin and avidin reagents in Coplin jars.

  1986cited by this paper
• Suppressor T cells in allogeneic models.

  1986cited by this paper
• Functional clonal deletion versus active suppression in transplantation tolerance induced by total-lymphoid irradiation.

  1985cited by this paper
• Chronic graft-versus-host disease as a model for scleroderma. II. Mast cell depletion with deposition of immunoglobulins in the skin and fibrosis.

  1985cited by this paper
• Reconstitution with syngeneic plus allogeneic or xenogeneic bone marrow leads to specific acceptance of allografts or xenografts

  1984cited by this paper
• Chronic graft-versus-host disease (GVHD) as a model for scleroderma. I. Description of model systems.

  1983cited by this paper
• Anti-recipient cytotoxic T lymphocyte precursors are present in the spleens of mice with acute graft versus host disease due to minor histocompatibility antigens.

  1981cited by this paper
• T cell growth factor abrogates concanavalin A-induced suppressor cell function

  1981cited by this paper
• A Single Major Pathway of T‐Lymphocyte Interactions in Antigen‐Specific Immune Suppression

  1981cited by this paper
• Rapamycin (AY-22,989), a new antifungal antibiotic. III. In vitro and in vivo evaluation.

  1978cited by this paper
• Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle.

  1975cited by this paper
• Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization.

  1975cited by this paper

• Graft-Versus-Host Disease Mouse Models: A Clinical-Translational Perspective.

  2025cites this paper
• Rapamycin Treatment Alleviates Chronic GVHD-Induced Lupus Nephritis in Mice by Recovering IL-2 Production and Regulatory T Cells While Inhibiting Effector T Cells Activation

  2023cites this paper
• Immunometabolic Therapeutic Targets of Graft-versus-Host Disease (GvHD)

  2021cites this paper
• How to Make an Immune System and a Foreign Host Quickly Cohabit in Peace? The Challenge of Acute Graft-Versus-Host Disease Prevention After Allogeneic Hematopoietic Cell Transplantation

  2020cites this paper
• Expanding Diversity and Common Goal of Regulatory T and B Cells. II: In Allergy, Malignancy, and Transplantation

  2017cites this paper
• Suppressor Properties of Human CD8+CD28− T Cells in Mixed Leukocyte Reaction are not Affected by CsA and RAPA

  2016cites this paper
• Ergebnisse einer retrospektiven Analyse zur Wirksamkeit von Everolimus bei der Behandlung der chronischen Graft-versus-Host Erkrankung

  2016cites this paper
• Rapamycin and dietary restriction induce metabolically distinctive changes in mouse liver.

  2015cites this paper
• The Endothelial Response to Injury: Defining the Role of Epidermal Growth Factor-like Domain 7 and Endothelial Protective Strategies

  2014cites this paper
• Sirolimus-FKBP12.6 Impairs Endothelial Barrier Function Through Protein Kinase C-&agr; Activation and Disruption of the p120–Vascular Endothelial Cadherin Interaction

  2013cites this paper
• Adenosine A2A Receptor Agonist–Mediated Increase in Donor-Derived Regulatory T Cells Suppresses Development of Graft-versus-Host Disease

  2013cites this paper
• A diagnostic window for the treatment of acute graft-versus-host disease prior to visible clinical symptoms in a murine model

  2013cites this paper
• Everolimus improves experimental autoimmune uveoretinitis.

  2012cites this paper
• DENDRITIC CELLS REGULATE THE INDUCTION OF EFFECTOR AND MEMORY CD8+ T CELLS

  2012cites this paper
• Effect of rapamycin on immunity induced by vector-mediated dystrophin expression in mdx skeletal muscle

  2012cites this paper
• Novel mechanism of rapamycin in GVHD: increase in interstitial regulatory T cells

  2010cites this paper
• Treatment with rapamycin prevents fibrosis in tight-skin and bleomycin-induced mouse models of systemic sclerosis.

  2010cites this paper
• Effects of manipulating the immune system on dystrophin gene transfer and dystrophic phenotype in striated muscles of Duchenne muscular dystrophy model, mdx mouse

  2010cites this paper
• Separating graft-versus-leukemia from graft-versus-host disease in allogeneic hematopoietic stem cell transplantation.

  2009cites this paper
• Review of Novel Immunotherapeutic Strategies for MS

  2007cites this paper
• Multiple-Sklerose-Update zur Pathophysiologie und neuen immuntherapeutischen Ansätzen

  2007cites this paper
• Rapamycin Promotes Emergence of IL-10-Secreting Donor Lymphocyte Infusion-Derived T Cells Without Compromising Their Graft-Versus-Leukemia Reactivity

  2007cites this paper
• [Update on pathophysiologic and immunotherapeutic approaches for the treatment of multiple sclerosis].

  2007cites this paper
• Ex vivo rapamycin generates Th1/Tc1 or Th2/Tc2 Effector T cells with enhanced in vivo function and differential sensitivity to post-transplant rapamycin therapy.

  2006cites this paper
• Characterization of the Optimal Culture Conditions for Clinical Scale Production of Human Mesenchymal Stem Cells

  2006cites this paper
• Key factors in experimental mouse hematopoietic stem cell transplantation

  2006cites this paper
• Rapamycin (sirolimus) for treatment of chronic graft-versus-host disease.

  2005cites this paper
• Prevention of lethal acute GVHD with an agonistic CD28 antibody and rapamycin.

  2005cites this paper
• Immunopathogenesis of acute graft-versus-host disease: implications for novel preventive and therapeutic strategies

  2004cites this paper
• New immunosuppressants with potential implication in multiple sclerosis.

  2004cites this paper
• rapamycin Prevention of lethal acute GVHD with an agonistic CD 28 antibody and

  2004cites this paper
• Acceleration of apoptosis in CD4+CD8+ thymocytes by rapamycin accompanied by increased CD4+CD25+ T cells in the periphery1

  2004cites this paper
• Monoclonal antibodies for the prevention and treatment of graft-versus-host disease.

  2003cites this paper
• Experimental Mouse Model of Scleroderma/Graft versus Host Disease: Induction by Transfer of Cellular Immmunity

  2003cites this paper
• Inducing tolerance to MHC-matched allogeneic islet grafts in Diabetic NOD mice by simultaneous islet and bone marrow transplantation under nonirradiative and nonmyeloablative conditioning therapy

  2002cites this paper
• Morbidity and mortality of chronic GVHD after hematopoietic stem cell transplantation from HLA-identical siblings for patients with aplastic or refractory anemias.

  2002cites this paper
• Photoreduction of the chloropropionic acid of carfentrazone-ethyl in sodium sulfide [corrected].

  2002cites this paper
• MECHANISMS OF TOLERANCE INDUCED BY PG490‐88 IN A BONE MARROW TRANSPLANTATION MODEL

  2002cites this paper
• Immunomodulation in stem-cell transplantation.

  2002cites this paper
• Rapamycin and T cell costimulatory blockade as post-transplant treatment promote fully MHC-mismatched allogeneic bone marrow engraftment under irradiation-free conditioning therapy

  2002cites this paper
• Understanding the alloresponse: new approaches to graft-versus-host disease prevention.

  2002cites this paper
• New developments in the prophylaxis and treatment of graft versus host disease

  2001cites this paper
• Pathogenesis and prevention of graft-versus-host disease

  2001cites this paper